Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study

Lancet Oncology

Volumn 7, Issue 3, 2006, Pages 223-229

  Domchek, Susan M ^a,b   Friebel, Tara M ^b   Neuhausen, Susan L ^c   Wagner, Theresa ^d   Evans, Gareth ^e   Isaacs, Claudine ^f   Garber, Judy E ^g   Daly, Mary B ^h   Eeles, Rosalind ⁱ   Matloff, Ellen ^j   Tomlinson, Gail E ^k   Van't Veer, Laura ^l   Lynch, Henry T ^m   Olopade, Olufunmilayo I ⁿ   Weber, Barbara L ^a,b,o   Rebbeck, Timothy R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e ST MARY S HOSPITAL   (United Kingdom)

^f GEORGETOWN UNIVERSITY   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^j YALE CANCER CENTER   (United States)

^k UNIVERSITY OF TEXAS AT DALLAS   (United States)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

^m CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF CHICAGO   (United States)

^o GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; AWARENESS; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DISEASE CARRIER; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY;

ADULT; BREAST NEOPLASMS; FEMALE; FUNCTIONAL LATERALITY; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 33344469058     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70585-X     Document Type: Article

References (14)

1. TR Rebbeck HT Lynch SL Neuhausen et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 2002 1616-1622
2. ND Kauff JM Satagopan ME Robson et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 2002 1609-1615
3. TR Rebbeck AM Levin A Eisen et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers J Natl Cancer Inst 91 1999 1475-1479
4. N Peters SM Domchek A Rose et al. Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer Genet Test 9 2005 48-53
5. LA Keogh MC Southey J Maskiell et al. Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study Cancer Epidemiol Biomarkers Prev 13 2004 2258-2263
6. B Fisher JP Costantino DL Wickerham et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371-1388
7. HM Klaren LJ van't Veer FE van Leeuwen et al. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation J Natl Cancer Inst 95 2003 941-947
8. LC Hartmann A Degnim DJ Schaid Prophylactic mastectomy for BRCA1/2 carriers: Progress and more questions J Clin Oncol 22 2004 981-983
9. S Wacholder Bias in intervention studies that enroll patients from high-risk clinics J Natl Cancer Inst 96 2004 1204-1207
10. Early Breast Cancer Trialists Collaborative Group Ovarian ablation in early breast cancer: Overview of the randomised trials Lancet 348 1996 1189-1196
11. ES Tambor BA Bernhardt G Geller et al. Should women at increased risk for breast and ovarian cancer be randomized to prophylactic surgery? An ethical and empirical assessment J Womens Health Gend Based Med 9 2000 223-233
12. SR Lakhani MJ Van De Vijver J Jacquemier et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 20 2002 2310-2318
13. A Antoniou PD Pharoah S Narod et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies Am J Hum Genet 72 2003 1117-1130
14. TR Rebbeck T Friebel T Wagner et al. Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers J Clin Oncol 23 2005 7491-7496